Education
About Us
Working with TipRanks
Follow Us
Anixa Biosciences (ANIX)
NASDAQ:ANIX
ANIX Stock Chart & Stats
$4.29
-$0.08(-3.60%)
At close: 4:00 PM EST
$4.29
-$0.08(-3.60%)
Day’s Range― - ―
52-Week Range$2.07 - $5.46
Previous CloseN/A
Volume56.82K
Average Volume (3M)393.49K
Market Cap
$104.68M
Enterprise ValueN/A
Total Cash (Recent Filing)$16.03M
Total Debt (Recent Filing)$213.00K
Price to Earnings (P/E)―
Beta0.50
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding32,916,916
10 Day Avg. Volume127,669
30 Day Avg. Volume393,490
Financial Highlights & Ratios
PEG Ratio-0.41
Price to Book (P/B)5.58
Price to Sales (P/S)0.00
P/FCF Ratio-15.22
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$14.00Price Target Upside226.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.35
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentAnixa announced it executed a Data Transfer agreement with Cleveland Clinic, enabling transfer of P1 breast cancer vaccine study data, a key step toward assuming full IND sponsorship.
Financial StabilityWith $17.3M in cash, and a low burn rate, Anixa should have runway into FY27 and through key events generated by its partnerships to unlock investor value.
Strategic PartnershipsAnixa's strategic partnerships with leading cancer centers like Cleveland Clinic and Moffitt Cancer Center both validate its programs and ensures efficient capital use while the programs work toward generating clinical proof of concept which should pave the way to later-stage studies.
Bears Say
Anixa Biosciences News
ANIX FAQ
What was Anixa Biosciences’s price range in the past 12 months?
Anixa Biosciences lowest stock price was $2.07 and its highest was $5.46 in the past 12 months.
What is Anixa Biosciences’s market cap?
Anixa Biosciences’s market cap is $104.68M.
When is Anixa Biosciences’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Anixa Biosciences’s earnings last quarter?
Anixa Biosciences released its earnings results on Mar 10, 2023. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.16 by $0.08.
Is Anixa Biosciences overvalued?
According to Wall Street analysts Anixa Biosciences’s price is currently Undervalued.
Does Anixa Biosciences pay dividends?
Anixa Biosciences does not currently pay dividends.
What is Anixa Biosciences’s EPS estimate?
Anixa Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Anixa Biosciences have?
Anixa Biosciences has 32,916,916 shares outstanding.
What happened to Anixa Biosciences’s price movement after its last earnings report?
Anixa Biosciences reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.16. Following the earnings report the stock price went down -5.797%.
Which hedge fund is a major shareholder of Anixa Biosciences?
Currently, no hedge funds are holding shares in ANIX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Anixa Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.00 (226.34% Upside)
$14.00 (226.34% Upside)
Blogger Sentiment
Bullish
ANIX Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 19.9%
Last 30 Days ▲ 19.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.33%
12-Months-Change
Fundamentals
Return on Equity
-57.94%
Trailing 12-Months
Asset Growth
-22.95%
Trailing 12-Months
Company Description
Anixa Biosciences
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
ANIX Stock 12 Month Forecast
Average Price Target
$14.00
▲(226.34% Upside)
Technical Analysis
Atossa Therapeutics
―
Champions Oncology
―
OKYO Pharma Limited Sponsored ADR
―
Contineum Therapeutics, Inc. Class A
―
Actuate Therapeutics, Inc.
―
Ownership Overview
5.40% Insiders
4.72% Mutual Funds
3.54% Other Institutional Investors
82.41% Public Companies and
Individual Investors